Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
22 März 2023 - 12:04PM
Edgar (US Regulatory)
FORM
6-K
SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
Report
of Foreign Issuer
Pursuant to Rule
13a-16 or 15d-16 of
the
Securities Exchange Act of 1934
For the
month of March 2023
Commission File
Number: 001-11960
AstraZeneca
PLC
1
Francis Crick Avenue
Cambridge
Biomedical Campus
Cambridge CB2
0AA
United
Kingdom
Indicate by check
mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.
Form
20-F X Form 40-F __
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(1):
Indicate by check
mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): ______
Indicate by check
mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
Yes __
No X
If
“Yes” is marked, indicate below the file number assigned to the
Registrant in connection with Rule 12g3-2(b):
82-_____________
AstraZeneca
PLC
INDEX
TO EXHIBITS
22 March 2023 11:00 GMT
Notice of Annual General Meeting and Board Committee
change
AstraZeneca
PLC (the Company) announced today the publication of its Notice of
Annual General Meeting 2023 and Shareholders’ Circular (the
Notice).
The Company also announced that, in line
with the UK Corporate Governance Code, Michel Demaré will step down
as a member of the Audit Committee at the conclusion of this year’s
Annual General Meeting (AGM) following his appointment as Chair of
the Board.
The Notice and the proxy form for the AGM have
been submitted to the National Storage Mechanism and will shortly
be available for inspection at https://data.fca.org.uk/#/nsm/nationalstoragemechanism.
The Notice is also available on the Company's website at
www.astrazeneca.com/noticeofmeeting2023.
The
Company's Annual Report and Form 20-F Information 2022 (the Annual
Report) was published on 21 February 2023.
The
Notice is being despatched to shareholders today.
The
meeting place for the AGM will be the Leonardo Royal Hotel London
Tower Bridge, 45 Prescot Street, London, E1 8GP and the AGM will
commence at 2.30 pm (BST) on 27 April 2023.
The
business to be conducted at the AGM is summarised
below:
1.
To
receive the Company’s Accounts, the Reports of the Directors and
Auditor and the Strategic Report for the year ended 31 December
2022
3.
To
reappoint PricewaterhouseCoopers LLP as Auditor
4.
To
authorise the Directors to agree the remuneration of the
Auditor
5.
To
elect or re-elect Directors
6.
To
approve the Annual Report on Remuneration for the year ended 31
December 2022
7.
To
authorise limited political donations
8.
To
authorise the Directors to allot shares
9.
To
authorise the Directors to disapply pre-emption rights
10.
To
authorise the Directors to further disapply pre-emption rights for
acquisitions and specified capital investments
11.
To
authorise the Company to purchase its own shares
12.
To
reduce the notice period for general meetings
13.
To
adopt new Articles of Association of the Company.
Pursuant to Regulation 41 of the Uncertificated
Securities Regulations 2001, only holders of ordinary shares
entered in the register of members of the Company by 6.30pm (BST)
on 25 April 2023 (or their duly appointed proxies), or if this
meeting is adjourned, in the register of members by 6.30pm (BST)
two days prior to any adjourned meeting, are entitled to attend or
vote at the AGM in respect of the number of ordinary shares
registered in their name at that time. Changes to the entries in
the register of members after 6.30pm (BST) on 25 April 2023, or if
this meeting is adjourned, in the register of members after 6.30pm
(BST) two days prior to any adjourned meeting, shall be disregarded
in determining the rights of any person to attend or vote at the
AGM. The
Record Date applied to the Euroclear Sweden system to determine
entitlement to attend and vote at the AGM is close of business on
18 April 2023.
AstraZeneca
AstraZeneca
(LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and
commercialisation of prescription medicines in Oncology, Rare
Diseases, and BioPharmaceuticals, including
Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in
over 100 countries and its innovative medicines are used by
millions of patients worldwide. Please
visit astrazeneca.com and
follow the Company on Twitter @AstraZeneca.
Contacts
For
details on how to contact the Investor Relations Team, please click
here. For Media
contacts, click here.
Adrian
Kemp
Company
Secretary
AstraZeneca
PLC
SIGNATURES
Pursuant to the
requirements of the Securities Exchange Act of 1934, the Registrant
has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Date:
22 March
2023
|
|
By: /s/
Adrian Kemp
|
|
|
Name:
Adrian Kemp
|
|
|
Title:
Company Secretary
|
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Mai 2023 bis Jun 2023
AstraZeneca (NYSE:AZN)
Historical Stock Chart
Von Jun 2022 bis Jun 2023
